Acceptability: total withdrawals · acute mania
Lithium showed no clear difference in acceptability: total withdrawals compared with aripiprazole (moderate certainty).
1 finding from 1 review
Adverse event: tremor · acute mania
Lithium showed no clear difference in adverse events: tremor compared with aripiprazole (moderate certainty).
1 finding from 1 review
Adverse events: somnolence/sedation · acute mania
Lithium showed no clear difference in adverse events: somnolence/sedation compared with aripiprazole (moderate certainty).
1 finding from 1 review
Adverse events: clinically relevant (> 7%) weight gain · acute mania
Lithium showed no clear difference in adverse events: clinically relevant (> 7%) weight gain compared with aripiprazole (low certainty).
1 finding from 1 review
Global outcome ‐ need for benzodiazepine during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcomes: need for benzodiazepine 2 compared with OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Adverse effects: any serious, specific ‐ dystonia during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: any serious, specific ‐ dystonia during 24 hours compared with OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for rapid tranquillisation ‐ needing additional injection · patients with psychosis‐induced aggression or agitation
HALOPERIDOL may leads to lower repeated need for rapid tranquillisation ‐ needing additional… compared with OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE (low certainty).
1 finding from 1 review
Specific behaviours ‐ agitation: average change score at 2 hours CABS · patients with psychosis‐induced aggression or agitation
1 finding from 1 review
Relapse · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in global state: Relapse (any reason) ‐ long term Assessed by 5 blinded… compared with ORAL ARIPIPRAZOLE (low certainty).
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ long term compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Adverse events: General ‐ serious Unclear how these events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: General ‐ serious Unclear how these events were… compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Specific ‐ weight increase compared with ORAL ARIPIPRAZOLE (low certainty).
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Mental state · schizophrenia
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · schizophrenia
1 finding from 1 review
Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · schizophrenia
1 finding from 1 review